Table 2 Use of ASMs before and after the first, second, and third SE episodes; medications are divided into intravenously- and only orally available agents
From: Clinical characteristics and outcomes of patients with recurrent status epilepticus episodes
First SE episode (n = 80) | Second SE episode (n = 80) | Third SE episode (n = 22) | ||||
|---|---|---|---|---|---|---|
Before SE episode | After SE episode | Before SE episode | After SE episode * | Before SE episode | After SE episode# | |
Intravenous-available ASMs | ||||||
Levetiracetam | 34 (42.5%) | 66 (82.5%) | 62 (77.5%) | 62 (87.3%) | 18 (81.8%) | 17 (80.9%) |
Valproate | 14 (17.5%) | 28 (35.0%) | 26 (32.5%) | 36 (50.7%) | 10 (45.5%) | 11 (52.4%) |
Lacosamide | 9 (11.3%) | 26 (32.5%) | 25 (31.3%) | 34 (47.9%) | 5 (22.7%) | 10 (47.6%) |
Phenytoin | 1 (1.3%) | 3 (3.8%) | 1 (1.3%) | 8 (11.3%) | 2 (9.1%) | 5 (23.8%) |
Phenobarbital | 1 (1.3%) | 1 (1.3%) | 1 (1.3%) | 2 (2.8%) | 1 (4.5%) | 1 (4.8%) |
Brivaracetam | – | 1 (1.3%) | 1 (1.3%) | 2 (2.8%) | – | – |
Only oral-available ASMs | ||||||
Lamotrigine | 9 (11.3%) | 9 (11.3%) | 8 (10.0%) | 11 (15.5%) | 4 (18.2%) | 3 (14.3%) |
Topiramate | 5 (6.3%) | 12 (15.0%) | 8 (10.0%) | 15 (21.1%) | 5 (22.7%) | 8 (38.1%) |
Zonisamide | 4 (5.0%) | 6 (7.5%) | 6 (7.5%) | 5 (7.0%) | 2 (9.1%) | 2 (9.5%) |
Perampanel | 1 (1.3%) | 2 (2.5%) | 1 (1.3%) | 4 (5.6%) | 1 (4.5%) | 1 (4.8%) |
No ASM intake | 32 (40.0%) | – | 8 (10.0%) | 1 (1.4%) | 1 (4.5%) | – |